This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Winning Stocks Backed by the Overlooked Rising P/E Ratio
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.
Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 21.31% and 1.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Owens & Minor (OMI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Owens & Minor (OMI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Owens & Minor (OMI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $42.06, marking no change from the previous day.
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $42.06 in the latest trading session, marking a -0.64% move from the prior day.
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed the most recent trading day at $41.17, moving -1.39% from the previous trading session.
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $44.27, marking a -1.49% move from the previous day.
Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $46.01, marking a -1.65% move from the previous day.
Owens & Minor (OMI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $46.90, marking a +1.16% move from the previous day.
Medtronic's (MDT) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fourth-quarter results reflect a strong recovery in terms of elective procedures.
Why Owens & Minor (OMI) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Owens & Minor (OMI).
Strength Seen in Owens & Minor (OMI): Can Its 36.2% Jump Turn into More Strength?
by Zacks Equity Research
Owens & Minor (OMI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down
by Zacks Equity Research
Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.
Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.
6 Valuable Price-to-Book Stocks to Boost Your Portfolio
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Top Ranked Growth Stocks to Buy for May 21st
by Zacks Equity Research
COLM, OMI, AN, and HRI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2021
Add These 5 Low P/CF Stocks to Create a Value-Based Portfolio
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Boise Cascade Company (BCC), Vishay Intertechnology (VSH), Owens & Minor (OMI), Sanmina Corporation (SANM) and Invesco (IVZ) boast low P/CF ratio.
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
by Zacks Equity Research
The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic
by Zacks Equity Research
On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.
LabCorp's (LH) Pixel Kit Gets EUA for Younger Population
by Zacks Equity Research
LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.